Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Racial Disparities in NK1 Receptor Antagonist Use

Breast Cancer Res Treat; ePub 2016 Mar 11; Check, et al

Racial disparities were evident in the use of oral neurokinin-1 receptor antagonists (NK1) to prevent chemotherapy–induced nausea and vomiting (CINV) among women with breast cancer and these disparities may be partly explained by racial differences in socioeconomic status. This according to study of 1,130 black and white women initiating highly emetogenic chemotherapy for the treatment of early-stage breast cancer. Researchers found:

• Racial disparities were observed in use of any NK1 (adjusted risk ratio, 0.68) and in use of oral aprepitant specifically (aRR, 0.54).

• There were no disparities in intravenous fosaprepitant use.

• After controlling for variables related to socioecomonic status, disparities in NK1 use were reduced but not eliminated.

Citation: Check DK, Reeder-Hayes KE, Basch EM, Zullig LL, Weinberger M, Dusetzina SB. Investigating racial disparities in use of NK1 receptor antagonists to prevent chemotherapy-induced nausea and vomiting among women with breast cancer. [Published online ahead of print March 11, 2016]. Breast Cancer Res Treat. doi:10.1007/s10549-016-3747-6.